Tim Adams Joins SS Innovations Board

SS Innovations International Inc. has added Tim Adams to its Board of Directors. He will serve as an independent director.

“I am very pleased that Tim will be joining us during the most robust phase of global growth to date, his appointment is perfectly timed. As a leader with some of the largest U.S. hospital systems, Tim offers us a unique insight into the markets for our system and should prove invaluable as we enter the US and other markets around the world,” SS Innovations Chairman/CEO Dr. Sudhir Srivastava said.
 
Adams has more than 40 years of hospital operations experience. Since January 2018, he has occupied various executive positions with one of the largest healthcare providers in the United States. Since March 2024, he has served as a regional operating officer with Ascension, where he oversees all of Ascension’s high-growth Horizontal Business Units including ambulatory surgery centers, outpatient imaging, outpatient/inpatient physical therapy, pharmacy, urgent care, behavioral, and post-acute/at-home services. He joined Ascension in early 2018 initially serving as market chief executive officer for Ascension Tennessee. In January 2023, he was promoted to senior vice president/regional operating officer, responsible for Ascension’s Florida, Indiana, Alabama, Kansas, Maryland, New York, Oklahoma, Tennessee and Texas ministry markets.

For approximately six years before joining Ascension, Adams was a region chief executive officer of one of the largest regions of Tenet Healthcare Corporation. Before that, he served in various senior executive positions with other for-profit hospital companies including Community Health Systems, HCA, IASIS and Health Management Associates. Adams also currently serves as chairman of the Tennessee Hospital Association in addition to various other community boards. Given his extensive experience in the U.S. healthcare market, Adams is expected to be a valuable member of SS Innovation’s board, especially as it works to obtain U.S. Food and Drug Administration (FDA) approval to market and expand the sales of its SSi Mantra system in the United States.
 
“I am honored to have joined the Board of SS Innovations. The hospital sector, especially on the non-profit side, is a very thinly margined business and highly capital intensive. There is thus a tremendous opportunity to offer an alternative to existing surgical robotic solutions at a significantly lower price point that is still competitive in what it has to offer,” Adams stated. “I believe the SSI’s Mantra system does just that. I am also excited about the future potential of telesurgery and capabilities of the Mantra to meet those needs. The ability to leverage the particular skill set of a robotic surgeon over a large geography will be transformational. This could also have applications in the U.S., where large health systems such as ours could eventually create surgical centers of excellence and leverage those centers across their enterprise along with their affiliated systems. This in turn would of course accelerate the need for robotic surgical systems. There is also tremendous opportunity to introduce an affordable robotic surgical system to the almost 10,000 and growing ambulatory surgery centers across the U.S.”
 
Earlier this year, SS Innovations launched the SSI Mantra 3, the newest and most advanced version of its surgical robotic system that makes possible more affordable and accessible surgical care across the globe.
 
The SSi Mantra 3 provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and telesurgery while engaging with surgeons and surgical teams to improve safety and efficiency during procedures. The regulatory approval process from the FDA is already underway, and SS Innovations anticipates receiving approval to market in the second half of 2025.
 
SS Innovations International is a developer of surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. 
 
Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more. With its modular arm configuration, 3D 4K vision open-console design and superior ergonomics, the system engages with the surgeon and surgical teams to improve safety and efficiency during procedures. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 80 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union.